Literature DB >> 34023900

A comprehensive review of m6A/m6Am RNA methyltransferase structures.

Stephanie Oerum1, Vincent Meynier1, Marjorie Catala1, Carine Tisné1.   

Abstract

Gene expression is regulated at many levels including co- or post-transcriptionally, where chemical modifications are added to RNA on riboses and bases. Expression control via RNA modifications has been termed 'epitranscriptomics' to keep with the related 'epigenomics' for DNA modification. One such RNA modification is the N6-methylation found on adenosine (m6A) and 2'-O-methyladenosine (m6Am) in most types of RNA. The N6-methylation can affect the fold, stability, degradation and cellular interaction(s) of the modified RNA, implicating it in processes such as splicing, translation, export and decay. The multiple roles played by this modification explains why m6A misregulation is connected to multiple human cancers. The m6A/m6Am writer enzymes are RNA methyltransferases (MTases). Structures are available for functionally characterized m6A RNA MTases from human (m6A mRNA, m6A snRNA, m6A rRNA and m6Am mRNA MTases), zebrafish (m6Am mRNA MTase) and bacteria (m6A rRNA MTase). For each of these MTases, we describe their overall domain organization, the active site architecture and the substrate binding. We identify areas that remain to be investigated, propose yet unexplored routes for structural characterization of MTase:substrate complexes, and highlight common structural elements that should be described for future m6A/m6Am RNA MTase structures.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2021        PMID: 34023900     DOI: 10.1093/nar/gkab378

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  33 in total

Review 1.  Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.

Authors:  Jiamin Guo; Yanzhong Yang; Ralf Buettner; Steven T Rosen
Journal:  Curr Opin Oncol       Date:  2022-07-05       Impact factor: 3.915

Review 2.  The Critical Role of RNA m6A Methylation in Gliomas: Targeting the Hallmarks of Cancer.

Authors:  Zhouhan Xu; Jun Jiang; Shun Wang
Journal:  Cell Mol Neurobiol       Date:  2022-09-15       Impact factor: 4.231

3.  NMDAR mediated dynamic changes in m6A inversely correlates with neuronal translation.

Authors:  Naveen Kumar Chandappa Gowda; Bharti Nawalpuri; Sarayu Ramakrishna; Vishwaja Jhaveri; Ravi S Muddashetty
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

4.  METTL3 mediates Ang-II-induced cardiac hypertrophy through accelerating pri-miR-221/222 maturation in an m6A-dependent manner.

Authors:  Rui Zhang; Yangyang Qu; Zhenjun Ji; Chunshu Hao; Yamin Su; Yuyu Yao; Wenjie Zuo; Xi Chen; Mingming Yang; Genshan Ma
Journal:  Cell Mol Biol Lett       Date:  2022-07-14       Impact factor: 8.702

Review 5.  The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer.

Authors:  Lin Luo; Yingwei Zhen; Dazhao Peng; Cheng Wei; Xiaoyang Zhang; Xianzhi Liu; Lei Han; Zhenyu Zhang
Journal:  Cell Death Discov       Date:  2022-07-18

Review 6.  Progress and application of epitranscriptomic m6A modification in gastric cancer.

Authors:  Yitian Xu; Chen Huang
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

Review 7.  Role of m6A Methylation in the Occurrence and Development of Heart Failure.

Authors:  Shaowei Fan; Yuanhui Hu
Journal:  Front Cardiovasc Med       Date:  2022-06-24

Review 8.  The emerging importance of METTL5-mediated ribosomal RNA methylation.

Authors:  Elena M Turkalj; Caroline Vissers
Journal:  Exp Mol Med       Date:  2022-10-21       Impact factor: 12.153

9.  Gene signature of m6A RNA regulators in diagnosis, prognosis, treatment, and immune microenvironment for cervical cancer.

Authors:  Shizhi Wang; Bo Ding; Shiyuan Wang; Wenjing Yan; Qianqian Xia; Dan Meng; Shuqian Xie; Siyuan Shen; Bingjia Yu; Haohan Liu; Jing Hu; Xing Zhang
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

Review 10.  Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer.

Authors:  Qiang Liu
Journal:  Front Genet       Date:  2022-01-11       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.